On May 10 2022, the Covid-19 Antigen CARD Kit (the Kit) self-developed by Fosun Diagnostics, a subsidiary company of Fosun Pharma was awarded the CE certificate and it will be now made available across 27 EU countries as well as regions that recognize the CE marked.
This Kit has significant advantages such as being accurate, fast and convenient which can be easily performed by individuals with results obtained only in 15 minutes. Applicable to the rapid testing in hospitals, CDCs, customs, airports, communities, schools, companies and other COVID-19 hot spot management as part of our efforts in continuous contribution toward the prevention and control of COVID-19 pandemic worldwide.
Prior to the CE marked, the Kit had also obtained BfArM registration in Germany, and endorsed by the EU Health Security Committee Common List (EU common list).
Fosun Diagnostics has developed an overall solution for 2019-nCoV testing, the COVID-19 RT-PCR Detection Kit is another classic product of Fosun Diagnostics with NMPA registration certificate, CE mark and FDA Emergency Use Authorization (EUA) and WHO Emergency Use Listing (EUL). The Company’s comprehensive range covers reagents, instruments, consumables, etc. have been successfully exported to numerous countries worldwide.